NASDAQ$RLMD
Relmada Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Relmada reported preliminary and unaudited financial results.
Relmada Therapeutics reported its Q4 and full year 2021 financial results, highlighting the completion of two human abuse potential studies confirming no meaningful abuse potential of REL-1017 and anticipating multiple key data readouts throughout the remainder of the year.
- Completed two human abuse potential (HAP) studies which confirmed no meaningful abuse potential of REL-1017 compared to oxycodone and ketamine.
- Anticipate multiple key data readouts throughout the remainder of the year.
- Expect data from RELIANCE III in mid-2022.
- Data in the third and fourth quarters from RELIANCE I and RELIANCE II.
Headline financials
Revenue & EPS history
Relmada · Revenue · Quarterly
-$9.87K
Forward guidance
Relmada anticipates multiple key data readouts throughout the remainder of the year, as the multiple ongoing clinical studies that comprise RELIANCE continue to progress.
Tailwinds
- Expect data from RELIANCE III in mid-2022
- Data in the third quarter from RELIANCE I
- Data in the fourth quarter from RELIANCE II
- REL-1017 has no meaningful abuse potential
- Strong balance sheet
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-1.6%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.2%
Avg return
30 days after
35%
15 / 43 earnings
Positive
+10.8%
Q4 2024
Best reaction
-29.0%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -12.5% | — | |
| Q1 2026 | +1.2% | -6.1% | -11.4% | |
| Q3 2025 | +1.8% | +7.7% | +4.6% | |
| Q2 2025 | -2.5% | -5.6% | +174.1% | |
| Q1 2025 | +6.6% | +33.4% | +53.6% | |
| Q4 2024 | +10.8% | -5.1% | +33.2% | |
| Q3 2024 | -3.5% | -2.9% | -86.5% | |
| Q2 2024 | -29.0% | -29.0% | -25.9% | |
| Q1 2024 | -0.5% | -7.6% | -22.8% | |
| Q4 2023 | -19.6% | -12.0% | -22.1% | |
| Q3 2023 | -2.0% | -7.5% | -16.1% | |
| Q2 2023 | +3.0% | +17.4% | +34.5% | |
| Q1 2023 | -9.2% | -10.7% | -19.0% | |
| Q4 2022 | -3.0% | +4.3% | +12.8% | |
| Q3 2022 | +10.4% | +2.3% | -53.5% | |
| Q2 2022 | -0.7% | -2.8% | +8.9% | |
| Q1 2022 | -12.4% | -18.5% | -20.1% | |
| Q4 2021 | +7.5% | +10.4% | +4.9% | |
| Q3 2021 | -8.2% | -12.0% | -24.4% | |
| Q2 2021 | +4.8% | +0.6% | +13.6% | |
| Q1 2021 | -4.1% | +0.0% | -10.9% | |
| Q4 2020 | -10.4% | -7.4% | +4.3% | |
| Q3 2020 | +0.0% | +8.3% | +0.9% | |
| Q2 2020 | -0.3% | +7.7% | +0.0% | |
| Q1 2020 | +9.6% | +8.5% | +12.6% | |
| Q4 2019 | -0.1% | -1.7% | +19.7% | |
| Q3 2019 | -3.0% | -5.1% | +29.9% | |
| Q2 2019 | -4.0% | -8.5% | +106.8% | |
| Q1 2019 | +0.0% | +1.7% | +13.9% | |
| Q3 2018 | +5.1% | +2.6% | -1.7% | |
| Q1 2018 | -5.0% | +5.3% | -13.3% | |
| Q2 2018 | +0.0% | -2.1% | -3.5% | |
| Q4 2017 | +4.7% | +4.7% | -11.0% | |
| Q3 2017 | -2.0% | -2.0% | -20.6% | |
| Q2 2017 | -8.6% | -4.8% | -32.9% | |
| Q1 2017 | +7.4% | +0.0% | -19.3% | |
| Q3 2016 | -17.8% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -1.1% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2014 | +4.2% | — | — | |
| Q3 2014 | -4.6% | — | — | |
| Q1 2015 | +5.9% | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro